Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 1, 2012, Pages

  Abimbola, Taiwo O ^a   Marston, Barbara J ^a   Date, Anand A ^a   Blandford, John M ^a   Sangrujee, Nalinee ^a   Wiktor, Stefan Z ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cost; Cost effectiveness; HIV; Sub Saharan Africa; Tuberculosis; Tuberculosis diagnosis

Indexed keywords

RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ARTICLE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MEDICAL PRACTICE; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PROBABILITY; SCREENING TEST; SENSITIVITY ANALYSIS; SPUTUM SMEAR; THORAX RADIOGRAPHY; TREATMENT DURATION; WORLD HEALTH ORGANIZATION;

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; CLINICAL LABORATORY TECHNIQUES; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; SURVIVAL ANALYSIS; TUBERCULOSIS;

EID: 84862127209     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318246538f     Document Type: Article

References (49)

1. WHO. Progress on Global Access to HIV Antiretroviral Therapy: An Update on "3 by 5". Geneva, Switzerland: WHO; 2005.
2. WHO. Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector. Geneva, Switzerland: WHO; 2010.
3. Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS. 2010;5:70-77.
4. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897-1908.
5. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS. 2010;5:18-26.
6. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS. 2007;21:713-719. (Pubitemid 46568628)
7. Lawn SD, Myer L, Bekker LG, et al. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20:1605-1612. (Pubitemid 44162402)
8. WHO. Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living With HIV in Resource Constrained Settings. Geneva, Switzerland: WHO; 2010.
9. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011;8:e1000391.
10. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis. 2009; 9:173-184.
11. WHO. Improving the Diagnosis and Treatment of Smear-Negative Pulmonary and Extrapulmonary Tuberculosis Among Adults and Adolescents: Recommendations for HIV-Prevalent and Resource-Constrained Settings. Geneva, Switzerland: WHO; 2006.
12. Dinnes J, Deeks J, Kunst H, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess. 2007;11:1-196.
13. Cepheid. GeneXpert system. Available at: http://genexpert.com/pdfs/ GeneXpert%20Brochure-0112-07.pdf. Accessed June 28, 2011.
14. WHO. Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert Mtb/Rif System. Geneva, Switzerland: WHO; 2011.
15. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1- infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367: 817-824.
16. Statistics South Africa. Historical Consumer Price Index. Available at: http://www.statssa.gov.za/registration/logon.asp. Accessed January 31, Pretoria, South Africa: Statistics South Africa; 2011.
17. Oanda. Average exchange rate. Available at: http://www.oanda.com/ currency/ average. Accessed January 31, 2011.
18. Haddix AC, Teutsch SM, Corso PS. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. New York, NY: Oxford University Press; 2003.
19. Briggs AH, Goeree R, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22:290-308. (Pubitemid 34791317)
20. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10: 779-787. (Pubitemid 34041389)
21. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362: 697-706.
22. Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis. 2010;51:823-829.
23. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;377:1495-1505.
24. Cain KP, McCarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med. 2010;362: 707-716.
25. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887-895. (Pubitemid 38553709)
26. Cruciani M, Scarparo C, Malena M, et al. Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. J Clin Microbiol. 2004;42:2321-2325. (Pubitemid 38637876)
27. Day JH, Charalambous S, Fielding KL, et al. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis. 2006;10:523-529. (Pubitemid 43667640)
28. Dowdy DW, O'Brien MA, Bishai D. Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Int J Tuberc Lung Dis. 2008;12:1021-1029.
29. Houlihan CF, Mutevedzi PC, Lessells RJ, et al. The tuberculosis challenge in a rural South African HIV programme. BMC Infect Dis. 2010;10:23.
30. Koenig SP, Riviere C, Leger P, et al. High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. Clin Infect Dis. 2009;48:829-831.
31. Lawn SD, Edwards DJ, Kranzer K, et al. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS. 2009;23: 1875-1880.
32. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS. 2001;15: 143-152. (Pubitemid 32142288)
33. Shah S, Demissie M, Lambert L, et al. Intensified tuberculosis case finding among HIV-infected persons from a voluntary counseling and testing center in Addis Ababa, Ethiopia. J Acquir Immune Defic Syndr. 2009;50:537-545.
34. Wester CW, Kim S, Bussmann H, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr. 2005;40: 336-343. (Pubitemid 41533075)
35. Westreich D, MacPhail P, Van Rie A, et al. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009;23: 707-715.
36. Monkongdee P, McCarthy KD, Cain KP, et al. Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am J Respir Crit Care Med. 2009; 180:903-908.
37. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471-1481.
38. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365: 1482-1491.
39. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. Geneva, Switzerland: WHO; 2010.
40. Chihota VN, Grant AD, Fielding K, et al. Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting. Int J Tuberc Lung Dis. 2010;14:1024-1031.
41. Dowdy DW, Chaisson RE, Maartens G, et al. Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A. 2008; 105:11293-11298.
42. Fairall L, Bachmann MO, Zwarenstein M, et al. Cost-effectiveness of educational outreach to primary care nurses to increase tuberculosis case detection and improve respiratory care: economic evaluation alongside a randomised trial. Trop Med Int Health. 2010.
43. WHO. Rapid Implementation of Xpert MTB/RIF Diagnostic Test. Geneva, Switzerland: WHO; 2010.
44. WHO. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Available at: http://www.who.int/choice/costs/unit-regions/en/index.html. Accessed March 29, 2011.
45. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa-a primary data analysis. Cost Eff Resour Alloc. 2006;4:20.
46. Rosen S, Long L, Sanne I. The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health. 2008;13:1005-1015.
47. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ. 2008;86:559-567. (Pubitemid 351931216)
48. World Bank. GDP Per Capita 2009. Available at: http://data.worldbank. org/country/south-africa. Accessed January 31, 2011.
49. Lawn SD, Kranzer K, Edwards DJ, et al. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS. 2010;24:1323-1328.